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Abstract
An in-depth overview of the normal-tissue radiation tolerance of the urinary bladder is presented.
The most informative studies consider whole-organ irradiation. The data on partial-organ/
nonuniform irradiation are suspect because the bladder motion is not accounted for, and many
studies lack long enough follow-up data. Future studies are needed.
1. Clinical Significance
Radiotherapy (RT) with or without chemotherapy for pelvic malignancies may result in
genitourinary (GU) complications. Overall, severe late effects occur in ≤10% of patients
with prostate, bladder, or cervical cancer (1). However, given a possible latency period of
several decades between treatment and the clinical manifestation of sequelae (2, 3), reports
may have underestimated the late GU toxicity rates. The reported rates of acute side effects
might be more accurate.
2. Endpoints
Many endpoints may be used to score bladder injury. In the present report, we focus on
clinical symptoms. The symptoms attributed to RT-related injury can also occur as a
consequence of other medical co-morbidities, such as infection or aging, particularly for
incontinence. The toxicity profile will depend on the treatment regimen of RT with or
without surgery or chemotherapy, and the origin, extent, and location of cancer. When
discussing bladder toxicities in relation to dose and/or volume, a significant heterogeneity of
dose can exist, depending on whether the patient has undergone brachytherapy, teletherapy,
or both, and on bladder motion.
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Acute side effects that occur during RT usually resolve within a few months. Long-term
symptoms attributable to global injury include dysuria, frequency, urgency, contracture,
spasm, reduced flow, and incontinence. In contrast, symptoms thought to arise from focal
injury include hematuria, fistula, obstruction, ulceration, and necrosis. The grading of
toxicities according to treatment given is subjective. One physician might prescribe an
intervention sooner than another, leading to a relative “upgrading.” Furthermore, symptoms
attributable to the bladder might be urethral in origin. Several scoring systems have been
proposed to standardize the reporting of bladder toxicity, each with a slightly different
approach. Some systems have separately considered objective vs. subjective endpoints (e.g.,
Late Effects of Normal Tissues-Subjective, Objective, Management and Analytic system
[LENT-SOMA]), and others have not differentiated between acute and late effects (e.g.,
Common Terminology Criteria for Adverse Events [CTCAE]) or have ambiguities (e.g.,
“spontaneous, pads indicated” is considered Grade 2 incontinence using the CTCAE).
Interstudy comparisons are challenging, because the scoring system used was not always
clearly stated. Furthermore, crude, rather than actuarial, rates have often been reported. In
general, patient-reported data have been shown to be superior to physician-reported data,
although the collection is more complex (4).
3. Challenges Defining Volumes
The bladder is a highly distensible organ. Its volume continuously changes with filling, and
the post-void residual volume can vary. Furthermore, the bladder can move with positioning,
respiration, or bowel filling. Therefore, we have referred to a dose–volume histogram
(DVH) of the bladder obtained from a single planning computed tomography (CT) image as
a “SimDVH” to emphasize that this image is unlikely to represent the true dose distribution
delivered to the bladder during the treatment course. The bladder trigone, which,
functionally, can be more important than the bladder dome, can be difficult to identify on
CT. Some reports have defined the bladder to include the entire organ (with urine), and
others have used the wall alone (excluding the urine). SimDVH-based and SimDose–
surface-histogram-derived metrics have a high degree of correlation (5), and future
comparisons of these with regard to late toxicity will provide useful information.
Theoretically, if the patient is treated with a constant bladder volume, the initial CT scan
(and associated SimDVH) would indicate the region receiving dose. However, many
patients cannot maintain a consistent bladder volume during the treatment course, and have
variable emptying and constant filling. Several studies have noted the nonstatic nature of the
bladder and reported wall and/or tumor movement of approximately 1–4 cm and volume
variations of ≤44%, using repeated CT scans during therapy (6–8). Determining a true
bladder DVH has not been feasible.
4. Review Of Dose–Volume Data
To date, no studies have comprehensively reported the true three-dimensional (3D) bladder
dosimetry in relation to toxicities. A single 3D image set (SimDVH) is of questionable
validity. Data for whole-bladder RT vs. partial-bladder doses are discussed by cancer type.
Bladder cancer
Table 1 lists selected series of patients treated with external-beam RT (EBRT) for bladder
cancer, often in conjunction with transurethral resection of the bladder tumor (TURBT) and/
or chemotherapy (9–19). Studies published before 1995 have been previously reviewed (1).
Figure 1 summarizes selected studies from that 1995 publication, as well as more recent
studies in which the whole bladder was treated with photons no more than once daily and
the corresponding Grade 3 or greater late toxicity rates were reported (9, 11–15, 20–26).
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Several different fractionation schedules were used; therefore, we plotted the toxicity rate
against the normalized total dose in 2-Gy fractions calculated using the linear-quadratic
model with an α/β of 6 Gy for consistency with the 1995 study by Marks et al. (1), although
others have reported using an α/β of 3 Gy. Two studies included in Fig. 1 reported late
toxicity rates of ≥25% with hypofractionated treatment schedules (20, 21), as did one study
of partial-bladder RT that used 2 Gy/fraction to a total of 62 Gy (15). Because these studies
used RT portals that encompassed the entire bladder with a margin large enough to account
for motion, we anticipated that the whole bladder received the prescription dose.
Nonetheless, a large variation was found in the reported severe late bladder toxicity rates,
indicating that an increasing dose does not account for all toxicity. Variations in reporting,
treatment received (with or without surgery and chemotherapy), radiation dose range within
a single study, and the modest number of patients in some studies have confounded the
interpretation.
For partial-bladder RT, care must be taken to ensure that the target volume is adequately
covered. Several fractionation patterns have been reported; one common regimen has been
whole-bladder RT to 52.5–55 Gy in 1.5–1.8-Gy fractions, followed by a partial-bladder
boost of 12–15 Gy using 1.5–1.8 Gy/fraction, resulting in a cumulative tumor dose of 64–65
Gy (27). The serious late complication rates were <25% for most of the two-phase studies
listed in Table 1(15–19), suggesting advantages for a boost strategy. The most recent update
of the Radiation Therapy Oncology Group bladder cancer trials of TURBT, chemotherapy,
and RT reported a late Grade 3 or greater GU toxicity rate of 6% (19). Although studies
have suggested that larger fraction size might increase the incidence of late complications
(12, 28), similar to accelerated fractionation (10), the currently available data are inadequate
to determine late bladder tolerance quantitatively for the range of doses encountered with
EBRT for bladder cancer.
Prostate cancer
The bladder neck and prostatic urethra are adjacent to, or within, the treated volume for
prostate cancer. The distinction between bladder and urethral symptoms cannot be reliably
made by the physician. The low rate of GU toxicity in post-prostatectomy series (29, 30)
suggests that the prostate and prostatic urethra, rather than the bladder, might cause most
GU symptoms. In the era before 3D imaging, a whole-pelvic approach, followed by a boost
to the prostate with a margin, resulted in the inferior part of the bladder receiving the full
dose. During the past decade, dose escalation and the use of conformal techniques, including
intensity-modulated RT (IMRT), have delivered high doses (≥70 Gy) to the prostate and,
hence, to the inferior portion of the bladder. With these techniques, the superior part of the
bladder is either outside the field for the entire treatment or receives approximately the full
dose from the first treatment phase but is outside the cone-down field. This is in contrast to
the trigone region, which lies immediately adjacent to the prostate and might receive the full
prescription dose.
The question of dose response for late GU toxicity in prostate-cancer treatment has not been
resolved. The vast majority of studies found no dose–volume relationship with regard to GU
toxicity. A few studies have indicated an association between the prostate dose and either
acute or chronic GU toxicity might exist. Dose-volume relationship studies have been
limited given the aforementioned constraints on localization of the bladder during treatment,
as well as the duration of follow-up necessary to determine chronic toxicity. In a randomized
multi-institutional trial of 669 prostate-cancer patients treated with 3D conformal RT, no
significant difference in late GU toxicity was noted between the 68-Gy and 78-Gy treatment
arms (31). With a median of 7 years of follow-up, the cumulative Grade 2 or greater toxicity
rates were 40% in the high-dose arm and 41% in the low-dose arm, and the cumulative
Grade 3 or greater toxicity rates were 13% and 12%, respectively. However, an overall dose
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response for Grade 2 or greater GU toxicity was noted in the most recent report of a single-
institution study of 1,571 patients by Zelef-sky et al. (32). They reported a cumulative 20%
incidence at 10 years after 81 Gy IMRT to the prostate compared with 12% for non-IMRT
patients treated to lower doses (32). However, in the entire cohort, only 3% developed Grade
3 GU toxicity, and no Grade 4 GU toxicity was noted. The median interval to the
development of symptoms was 30 months, and <1% developed late GU toxicity after 10
years. The investigators did not attempt to report the DVH values (32).
Gynecologic cancer
Historical data have indicated that locally advanced cervical cancer treated with high doses
(>60 Gy) of EBRT alone results in a high incidence of late GU toxicities and a poor
outcome (33). Therefore, a combination of EBRT and brachytherapy is used. The dose to the
entire bladder with EBRT typically ranges from 40 to 50 Gy, and the total dose with
brachytherapy to the region closest to the implant approximates 70–90 Gy and can reach
>100 Gy. However, these regions likely vary between fractions, resulting in an unknown
true maximum dose for most patients. The International Commission on Radiation Units
Report 38 system assigns a bladder dose point; however, this point is not representative of
the CT-based (34–38)or ultrasound-based (39) volumetric dose maximum and surface area
of normal tissue irradiated.
Contouring the bladder with a Foley catheter in place during each fraction of brachytherapy
more accurately determines the doses received by the bladder. With a median follow-up of
39 months, the mean D2cc of the bladder for 141 patients with locally advanced cervical
cancer treated with tandem and ring brachytherapy was 95.3 ± 21 Gy (α/β = 3); 3 patients
experienced Grade 3 or 4 late bladder toxicity, resulting in a 3-year actuarial rate of 4%. Of
those treated with a bladder dose to D2cc of <95 Gy, 13% (11 of 87) developed Grade 1–4
late toxicity compared with 17% (9 of 54) if that dose was >95 Gy. These differences were
not significant, indicating that the focal dose threshold is not clear from the available data
(40–42). No Grade 3 or 4 GU toxicities were reported for 10 patients treated with magnetic
resonance imaging-guided interstitial gynecologic brachytherapy with a median D2cc to the
bladder of 69 Gy after a 2-year median follow-up (43, 44). Longer follow-up of these studies
is needed.
5. Factors Affecting Risk
Co-morbidities
Among patients undergoing RT for prostate cancer, an increased risk of late GU toxicity has
been seen for patients with pre-RT GU morbidity (45–48) and/or acute GU toxicity. After
EBRT, an increased rate of Grade 2 or greater GU toxicity has been seen with increasing age
and the use of hormones. In cervical cancer, the 10-year bladder complication rate in a series
from the M.D. Anderson Cancer Center was 3%. On multivariate analysis, a central pelvic
dose of EBRT >50 Gy (hazard ratio [HR], 3.34; p = .002), black race (HR, 1.89; p = .003),
smoking history (HR, 1.81; p = .006), and body mass index >30 kg/m2 (HR, 1.55; p = .05)
were significantly associated with bladder complications (49). Age, diabetes, hypertension,
or a history of pelvic inflammatory disease were not significantly related to bladder toxicity
(49). From the experience of the senior investigators of the present report, patients taking
anticoagulation medications might develop hematuria.
Surgery
TURBP, prostatectomy, hysterectomy, biopsy or any kind of procedure before RT may
potentially increase morbidity. The site of TURBT might heal slowly. Hysterectomy or
prostatectomy can denervate the bladder, which causes urinary hesitancy or retention,
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resulting in overflow incontinence. Approximately 5% of patients who undergo radical
hysterectomy require chronic suprapubic catheterization; 38–50% develop detrusor
instability, impairment of bladder sensation, alteration in bladder compliance or capacity, or
a reduction in the maximal urethral pressure (50, 51). In one study (52), transurethral
prostate resection (TURP) before definitive RT resulted in incontinence in 5% of patients
compared with 1% who had not undergone TURP. After EBRT for prostate cancer, the rate
of urethral stricture has been reported to range from 2% to 5% in patients without previous
TURP vs. 6–16% in patients with previous TURP (1).
Chemotherapy
Changes in bladder function can occur with chemotherapy alone or with concurrent
chemoradiotherapy. Cytoxan is independently associated with chronic hemorrhagic cystitis,
incontinence, contractions, vesicoureteral reflux, and urothelial malignancies (53). In one
study with 8 years of follow-up of cervical-cancer patients treated with chemoradiotherapy,
3% developed late bladder side effects (54). During the past one to two decades, selective
bladder-preserving approaches for patients with muscle-invasive bladder cancer have
included EBRT with concurrent cisplatin-containing chemotherapy. Tumor doses of 64–65
Gy have been well tolerated (19). Chemotherapy administered concurrently with RT can
sensitize the normal tissue, although this has not been shown to increase the risk of long-
term bladder complications in patients with cervical cancer or bladder cancer.
Fractionation
Some evidence has supported the association of a high dose per fraction with a greater
complication rate (1). Prostate-cancer patients treated with 5.17 Gy/fraction twice a week
through anteroposterior/posteroanterior fields for 9 weeks with a 3-week break mid-way
through therapy had a 19% rate of serious bladder injury (55). These included both global
(cystitis and contracture) and focal (fistula) injury. Treatment timing could also be a factor.
One study of bladder cancer reported a 32% risk of severe bladder injury with a split-course
technique of 40 Gy to a large volume of the bladder (whole-pelvic fields), followed by 20
Gy (to a small portion of the bladder) at 2 Gy/fraction using two-dimensional simulation,
with three fractions daily and an inter-fraction interval of 4 h (56). A series using whole-
bladder RT for bladder cancer found that 66 Gy delivered within 5 weeks with 2 Gy/fraction
twice daily for the last 8 days, with at least a 6-h interval between fractions, resulted in no
Grade 3 or greater late GU toxicity at 3 years (10). However, twice-daily treatment for the
final 13 days (within 4 weeks total) significantly increased the 3-year actuarial GU toxicity
rate to 31% (p = .04) (10). In contrast, a randomized trial of 229 patients with muscle-
invasive bladder tumors treated without chemotherapy compared 60.8 Gy in 32 fractions
twice daily vs. daily RT to 64 Gy. There was no significant difference between accelerated
versus conventional fractionation in acute Grade 2 or 3 bladder toxicity (34% vs. 36%) or
late chronic hematuria (25% vs. 14%), increased frequence of micturition (60% vs. 66%) or
ureteric stenosis (11% vs. 9%) (57).
6/7. Mathematical/Biologic Models and Special Situations
Currently, no quantitative models are available that satisfactorily describe the observed
serious late bladder toxicity after EBRT, given the lack of a clear dose response for whole-
bladder RT and overall bladder variability. Given the marked uncertainty of the 3D data on
which previously described models were based, we do not recommend that any of the
previously described model coefficients be used to predict the outcome. Furthermore,
whether different parameter sets might be necessary to describe complications in the setting
of RT for prostate, bladder, or gynecologic cancer or in subpopulations of patients with
various co-morbidities is not known.
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8. Recommended Dose–Volume Limits
Although constraints have been used by some centers, the values of the set constraints have
often not been based on preceding data nor on localization of the bladder during fractionated
therapy. Unless treatment is to the whole pelvis, a bladder volume determined from a static
simulation CT scan will not represent the treated portion of the bladder during a several-
week course of therapy. In the absence of any reliable data, clinicians might consider the
dose limits listed in the conventional fractionation arm of the Radiation Therapy Oncology
Group (RTOG) 0415 study of prostate cancer, which included a solid bladder constraint of
no more than 15% of the volume to receive a dose >80 Gy, no more than 25% of the volume
to receive a dose >75 Gy, no more than 35% of the volume to receive a dose >70 Gy, and no
more than 50% of the volume to receive a dose >65 Gy.
Bladder cancer
The published reports have not provided robust data on which to base strict dose–volume
guidelines. Nevertheless, the published data have suggested that restricting whole-bladder or
partial-bladder doses to 64–65 Gy in 36 daily fractions or in 40–42 twice-daily fractions
produces a level of late bladder complications equivalent to Radiation Therapy Oncology
Group Grade 3 toxicity in ≤6% (19).
Prostate cancer
The dose distributions for conventional four- and six-field 3D conformal RT to the prostate
and seminal vesicles, with an approximately 1-cm margin, limit the volume of bladder
receiving the prescription dose. The resultant in-target dose distribution will be relatively
uniform, with high regions of dose within the bladder unlikely. For IMRT, physicists at
several centers use optimization to constrain the high-dose regions. Several different
constraints have been reported, although none have been determined from long-term toxicity
data, and all used the SimDVH. Increasingly, many centers use daily image guidance with
ultrasound or radiographic imaging of implanted markers for prostate localization. In the
future, imaging will allow clinicians to decrease the prescribed margin and might improve
our knowledge of the bladder location and delivered dose. Selected centers queried for the
present review do not apply bladder constraints when performing prostate brachytherapy.
Gynecologic cancer
The external-beam component of gynecologic therapy has been limited to 40–50 Gy and
rarely results in severe long-term sequelae. However, the addition of brachytherapy
increases this dose. In cervical-cancer brachytherapy, an upper dose limit for brachytherapy
has not yet been clearly defined (42).
9. Future Toxicity Studies
The upper limit of bladder dose tolerance is not known. Future studies detailing the dose–
volume data, accounting for organ motion and distension, and having long-term clinical
follow-up data are needed. In addition, reports in the future should attempt to address some
of the issues listed below.
The use of 3D imaging during conformal RT will facilitate studies that relate the actual
dose–volume parameters to the clinical outcomes.
An improved understanding of the physiology of bladder distention might allow
construction of deformable models that could facilitate estimates of bladder dose distribution
according to the bladder volume and surface area. Statistical methods might also be useful to
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understand the likely degree of bladder motion during a course of RT and to better estimate
the delivered 3D doses.
All regions of the bladder might not be equally important for different functions. Studies that
estimate the physiologic effect of doses to different regions of the bladder could be helpful.
Statistical approaches such as Cox regression proportional hazard models should be used to
adjust for the potential confounding effects of medical co-morbidities and other treatments.
Patients with recurrent disease should not be included in such studies because the symptoms
from recurrence and repeated treatment could be confounding.
Better determination of the linear-quadratic model parameters describing bladder injury is
needed. The radiobiologic determinants of the α/β and the biologic model used to calculate
a normalized total dose in 2-Gy fractions (EQD2) for high-dose-rate brachytherapy should
be analyzed to determine whether they are valid for the high doses administered during
cervical-cancer treatment. An increased understanding of the applicability of the model to
bladder injury, especially in the setting of brachytherapy, is needed.
Patient-based, rather than physician-derived, toxicity scoring must be reported to better
reflect the true symptomatic incidence of bladder injury.
10. Toxicity Scoring
Both physician- and patient-generated reports are important to assess toxicities. Symptoms
can be graded by patient report, including statements ranging from “not a problem” to “a big
problem.” Symptoms such as incontinence, hematuria, pads used daily, nocturia, dysuria,
frequency, and retention can be assessed with more validity using patient-assessment tools
rather than physician-assessment tools, including those that rely on medications prescribed.
Given the multiple endpoints that can be used to score toxicity, and to avoid ambiguity, we
recommend that objective, quantitative, scoring systems that explicitly consider multiple
patient- and physician-based endpoints be used, such as the LENT-SOMA system.
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Incidence of Radiation Therapy Oncology Group Grade 3 or greater late bladder toxicity in
relation to average dose (squares) or linear-quadratic model equivalent dose (triangles) in 2-
Gy fractions (assuming α/β = 6 Gy) for studies treating whole bladder only (listed in Table
1 and reviewed by Marks, et al. [1]). Letter in each square denotes data source: publication
specified in key as first author followed by superscript reference number. Note, Quilty and
Duncan (20) had four dose groups. Number of patients italicized inside each square. No
significant correlation was found between complication rate and either dose or equivalent
dose. (Courtesy of E.D. Yorke.)
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